Chest
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gorse, G.
Right arrow Articles by Munn, N.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Gorse, G.
Right arrow Articles by Munn, N.

Chest, Vol 100, 977-984, Copyright © 1991 by American College of Chest Physicians

ARTICLES

Superiority of live attenuated compared with inactivated influenza A virus vaccines in older, chronically ill adults

GJ Gorse, RB Belshe and NJ Munn
Department of Internal Medicine, St. Louis Veterans Affairs Medical Center, MO.

Forty-eight older adults with chronic diseases were vaccinated intranasally with live attenuated influenza A/Korea/1/82 (H3N2), CR59 virus. Forty-two (88 percent) CR59 virus recipients became infected with vaccine virus without adverse effects or change in mean pulmonary function even among the 29 infected recipients with moderate to severe chronic obstructive pulmonary disease. Among control groups who received either monovalent or trivalent inactivated influenza virus vaccines intramuscularly, the rates of fourfold rises in serum antibody titer to hemagglutinin (HA) were not different from the rate following CR59 virus inoculation. However, CR59 virus was superior to inactivated virus vaccine at stimulating secretory antibody to HA. Vaccinees age 65 years and older were more likely to shed CR59 virus in nasal secretions than were younger vaccinees, but antibody responses were not different. CR59 virus vaccine was safe and immunogenic in this population and more often induced a nasal wash IgA antibody response than the inactivated virus vaccines.


This article has been cited by other articles:


Home page
 Eur Respir JHome page
I. Stephenson and K.G. Nicholson
Influenza: vaccination and treatment
Eur. Respir. J., June 1, 2001; 17(6): 1282 - 1293.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
K. L. Nichol, P. M. Mendelman, K. P. Mallon, L. A. Jackson, G. J. Gorse, R. B. Belshe, W. P. Glezen, J. Wittes, and for the Live Attenuated Influenza Virus Vaccine in
Effectiveness of Live, Attenuated Intranasal Influenza Virus Vaccine in Healthy, Working Adults: A Randomized Controlled Trial
JAMA, July 14, 1999; 282(2): 137 - 144.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1991 by the American College of Chest Physicians.